Apotex Wins Tentative FDA Approval for Generic Ozempic

Regulatory Progress Across Borders

The tentative FDA approval represents a significant milestone for Apotex as the company works toward bringing affordable generic semaglutide to market. While this approval applies to the U.S. market, it demonstrates the company's manufacturing capabilities and regulatory compliance as similar applications progress through Health Canada's review process.

Apotex, based in Toronto, is among the generic manufacturers with applications currently under review by Health Canada for semaglutide products. The company's FDA milestone comes as Canadian patients await domestic approvals for generic alternatives.

Health Canada Review Status

Health Canada is currently reviewing nine applications for generic semaglutide from various manufacturers, with some applications filed as early as February 2024. The regulatory body has established a 180-day review timeline for generic applications, which is faster than many international standards.

Generic applications under review include submissions for products equivalent to Ozempic, Wegovy, and other semaglutide formulations. Patients can track the progress of these applications through our generic semaglutide tracker.

Canadian Generic Landscape

The patent for semaglutide expired in Canada on January 4, 2026, opening the door for generic competition. Several Canadian and international generic manufacturers have submitted applications to Health Canada, including:

• Sandoz - with multiple semaglutide formulation applications
• Teva - applications for various strengths
• Apotex - submissions currently under regulatory review
• Taro Pharmaceuticals - generic semaglutide applications
• Vimy Pharma - Canadian-manufactured generic applications

Market Impact Considerations

Industry analysts expect generic semaglutide to be priced significantly below current brand-name medications. Current pricing for brand-name products ranges from $300 to $570 monthly across Canadian pharmacies, including Shoppers Drug Mart, Costco, and Walmart.

The availability of generic alternatives is expected to impact both private insurance plans and public drug coverage decisions. Provincial formularies are monitoring Health Canada approvals to determine coverage policies for generic semaglutide products.

Timeline for Canadian Availability

While Apotex has achieved tentative FDA approval, the company's Health Canada application remains under review. Generic manufacturers typically cannot launch products until they receive Notice of Compliance from Health Canada, regardless of approvals in other jurisdictions.

Patients seeking information about generic availability and pricing can use our insurance coverage checker to understand current coverage options and prepare for potential generic launches.

Regulatory Requirements

Health Canada requires generic manufacturers to demonstrate bioequivalence to reference products and meet Canadian manufacturing standards. The tentative FDA approval for Apotex suggests the company has met similar regulatory requirements in the U.S. market.

Generic semaglutide products must match the strength, dosage form, and route of administration of reference medications like Ozempic and Wegovy. Manufacturers must also establish Canadian distribution and supply chains before market launch.